---
title: "Fosun Pharma’s CAR-T Therapy Application Accepted in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258681049.md"
description: "Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Kairos, has had its drug registration application for Brexucabtagene Autoleucel Injection accepted by the National Medical Products Administration in China. This CD19-targeted CAR-T cell therapy is aimed at treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The acceptance signifies a major advancement for Fosun Pharma in the biopharmaceutical sector. Analysts rate the stock (HK:2196) as a Buy with a price target of HK$35.30."
datetime: "2025-09-24T10:40:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258681049.md)
  - [en](https://longbridge.com/en/news/258681049.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258681049.md)
---

# Fosun Pharma’s CAR-T Therapy Application Accepted in China

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Kairos, has had its drug registration application for Brexucabtagene Autoleucel Injection accepted by the National Medical Products Administration. This product, a CD19-targeted CAR-T cell therapy, is intended for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The development of this therapy is based on technology transferred from Kite Pharma, a subsidiary of Gilead Sciences. The acceptance of this application marks a significant step for Fosun Pharma in expanding its portfolio of innovative treatments and strengthening its position in the biopharmaceutical industry.

The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

**More about Shanghai Fosun Pharmaceutical (Group) Co**

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company based in China, specializing in the development and production of therapeutic biological products. The company focuses on innovative healthcare solutions, including CAR-T cell therapies, and operates in both domestic and international markets.

**Average Trading Volume:** 11,475,661

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$86.28B

For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)

## Related News & Research

- [SpaceX is way ahead of competitors with Starlink, but growth is harder heading into IPO](https://longbridge.com/en/news/289515187.md)
- [CLPT sees 30% revenue growth on rising demand](https://longbridge.com/en/news/289491289.md)
- [BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance](https://longbridge.com/en/news/289523795.md)
- [SpaceX Prices Biggest Ever IPO At $135 Per Share](https://longbridge.com/en/news/289506657.md)
- [Saudi crown prince orders resumption of Lebanese exports](https://longbridge.com/en/news/289370386.md)